The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So the yearly filing has been made in the US. Looks like the board rewarded itself with a $13m bonus for doing the fund raise last year and the pipeline dates have changed also.
https://ir.tizianalifesciences.com/node/9426/html
I don't mind anyone earning a living but 13 million bonus for delivering nothing so far and now behind the original schedule and no accustem shares? As they say around my end they're taking the ****.
It’s a long read and most of it covers the many risks of the business. Can’t see this going anywhere near £2 in the next 24 mth, if ever. The board have done well for themselves, it’s now time for them to show something for investors. The institutions that raised the last money, will not be so willing next time after reading this
Only something truly unexpected and amazing from left field can justify this!
On page 83 of the filing you will see that the entire "Realisation" bonus of $13.5 million went entirely to GC in shares under an agreement originally struck between the company and GC in 2016. Although there is a generic explanation of the basis of how the amounts under the agreement are calculated on page 83, I can't how work out yet how the $13.5 million was arrived at. The shares seem to have been awarded at around $2.85 per share.
It does indeed seem to relate to fund-raising activities.
Has the rush to make money and promote the company by attaching the Covid-19 'tag' to products not developed for its treatment taken the focus away from their intended purpose? Sure seems that way if the pipeline targets are slipping.
At this point, the Accustem shares - when they finally do arrive - will do little more than offset the paper losses on TILS stock.
Yes the "Bonus" is only in name. An old agreement. AccuStem will do more than fill a "paper loss" hole for many and for me personally will derisk my investment almost entirely. Opinion only
Fools,
I think we should hold a view of mild skepticism until solid news is provided. At this rate the drift downwards will only resume without real news. IMO
Some times MMS try shaking before NEWS... this is BUY at this price
Leer,
I agree entirely. Healthy scepticism is needed otherwise wild optimism will blind you. I am just fortunate with entry point and time to spare the outlay. The stage we're at now is make or break in my opinion. AccuStem done and dusted, that's value already sorted. If (when) we get to phase III you'll see a lot of excitement and interest here again. Typical news/no-news cycle of pharmas imo
When do you think Tils will start a P3 trial?
I would say not before 2023 unless they are able to make rapid progress with Covid.
Not sure it's that relevant Sangi...they aren't going to do ph3 in isolation, it would be in partnership, so a lot of potential tie-ups on the way potentially. Also delivering P3 not a sole driver of value - as an example, Imutex, part owned by Open Orphan, will go to market in US through ConservBio at c.$600mn...ph2 complete, not started ph3. Have some pre-clinical stuff but mainly one drug, Imutex.
TILS has a lot more going for it. Quiet time now but moving in right direction, plenty of other shares if you don't see the value here... (not sure why I'm posting tbh, more for benefit of others I guess...)
NEWS could drop any time... this is TIME to BUY not SELL...
Couldn't agree more Green
A big bonus indeed.Even the more galling is the bankers and lawyers would have probably suggested this extra deal for another juicy commission no doubt!I'm more annoyed by that as the bankers obviously facilitate all this stuff and on aim we don't have any big activist funds (even if some of them don't get far nonetheless, it's better than nothing) or anything to at least give us retail pis any say or comeback.
Sorry i forgot we're main market now but still... at our current marketcap no major funds will be interested unfortunately.